Below you will find news and press releases from industry, government, and academia regarding product developments and medical/scientific research news.
Female triathletes are at a higher risk for several health issues, including pelvic floor disorders, new research indicates. Researchers conducted an internet survey of 311 self-identified female triathletes. Results showed a significant prevalence of pelvic floor disorders, with urinary incontinences (37.4 percent) and anal incontinence (28.0 percent) being the most common. Read more.
Source: Science Daily, August 23, 2016
Patricia Industries, a part of Investor AB, has signed an agreement with Audax Private Equity to acquire the Canadian medical technology company LABORIE, which focuses on the diagnosis and treatment of urologic and gastrointestinal disorders that affect the daily lives of millions. LABORIE was founded in 1967 and has grown organically and through acquisitions from a leading manufacturer of capital equipment for urodynamic testing into a fully-integrated medical device company with a market-leading position in urology and a rapidly growing gastroenterology business. Read more.
Source: Business Wire, August 19, 2016
BioLife Solutions, Inc.(BioLife, a leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media, announced that its media products are embedded into the autologous cell therapy being developed by Pittsburgh-based Cook MyoSite, a subsidiary of the Cook Group, for treatment of female stress urinary incontinence. Read more.
Source: PharmaBiz.com, July 19, 2016
DENVER – Analytica on Wednesday announced that the U.S. Food and Drug Administration has approved the PeriCoach at-home pelvic floor trainer device and smartphone app as an over-the-counter treatment for mild, moderate and stress urinary incontinence and urge incontinence. Pelvic floor muscle exercise is recommended as first line non-pharmacologic treatment for the millions of women – estimated at one in three – who suffer from urinary incontinence. Read more.
Source: Drug Store News, July 13, 2016
SRS Medical Systems (Feeding Hills, MA) landed CE Mark approval for its Spanner temporary prostatic stent for men with bladder outlet obstructions. The Spanner temporary prostatic stent is an option over Foley and intermittent catheters, which are commonly used these days. Read more.
Source: Medgadget, June 29, 2016
Every day, Domtar improves the quality of peoples’ lives by providing dignity and choice through its Personal Care products. In line with its strategy and core capabilities, Domtar Corporation (NYSE: UFS) (TSX: UFS) has purchased the assets of Butterfly Health Inc. BUTTERFLY® body liners offer discreet, secure protection for accidental bowel leakage (ABL). “This product provides a unique solution to a problem that exists for roughly 1 out of 10 people. It represents a complementary addition to our portfolio of brands and technologies,” stated Mike Fagan, President of Domtar Personal Care. Read more.
Source: Business Wire, June 27, 2016
Axonics Modulation Technologies won European regulatory approval for its Sacral Neuromodulation System (SNM), a product designed to treat overactive bladder, urinary retention, and fecal incontinence. The device is rechargeable, and so can be used for longer periods than similar devices that have to be replaced with new batteries periodically. Read more.
Source: Medgadget, June 7, 2016